博實股份(002698.SZ):收到已簽訂的1.016億元設備採購合同
格隆匯 9 月 28日丨博實股份(002698.SZ)公佈,近日,公司收到與新疆新冶能源化工股份有限公司(“新冶能源”)、新疆中泰化學股份有限公司(“中泰化學”)簽訂的“設備採購合同”,合同合計金額為人民幣10160萬元,新冶能源和中泰化學均為新疆中泰(集團)有限責任公司的子公司。根據公司《章程》等相關規定,該合同的簽署權限在總經理權限範圍內。
上述合同不含税合計金額為8991.15萬元,佔公司2019年度營業收入的6.16%。由於合同部分設備需經客户先置生產測試驗收,部分設備需根據後續客户生產運行情況進行驗收,預計對公司2020至2021年度業績有積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.